Anthem Biosciences gains 30% from its IPO price on Mumbai debut

Anthem Biosciences gains 30% from its IPO price on Mumbai debut

Anthem Biosciences, a leading contract research and manufacturing organization (CRDMO) based in Bengaluru, made its market debut today, July 21, with a significant gain from its initial public offering (IPO) price. The stock listed at Rs 723, representing a 27% premium over the IPO price of Rs 570, according to the grey market premium (GMP) [1].

The IPO, which was priced between Rs 540 and Rs 570 per share, was highly subscribed, with an overall subscription of 67.4 times. Qualified Institutional Buyers (QIBs) led the charge, subscribing 192.8 times their allotted quota, while Non-Institutional Investors (NIIs) followed with a 44.7 times bid, and the retail category was booked nearly 6 times [2].

Anthem Biosciences operates across the drug development lifecycle, providing end-to-end services for both small molecules and biologics. The company reported a 30% rise in revenue to Rs 1,930 crore and a 23% growth in net profit to Rs 451 crore for the fiscal year ending March 2025 [3].

The strong demand for Anthem Biosciences' shares is reflected in the GMP of Rs 169, indicating an estimated listing price of around Rs 739 per share, which is a 29.65% potential gain over the issue’s upper price band of Rs 570 per share [1].

The company's robust financial performance, high-margin model, and leadership position in the CRDMO space have drawn significant investor interest. However, the steep valuation and high premium listing will require close monitoring of its post-listing performance and growth trajectory [3].

References:
[1] https://www.financialexpress.com/market/ipo-news-anthem-bioscience-ipo-listing-today-big-debut-or-flat-start-heres-what-gmp-indicates-3920947/
[2] https://www.business-standard.com/markets/capital-market-news/anthem-biosciences-ipo-ends-with-63-86x-subscription-125071700340_1.html
[3] https://m.economictimes.com/markets/stocks/news/anthem-biosciences-ipo-listing-today-check-gmp-ahead-of-debut/articleshow/122804458.cms